48,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

This book is about "David & Goliath" partnerships in pharmaceutical R&D-collaborative arrangements between small biotech firms or academic laboratories (David) with multinational pharmaceutical corporations (Goliath) to discover, develop and commercialize innovative new drugs.

Produktbeschreibung
This book is about "David & Goliath" partnerships in pharmaceutical R&D-collaborative arrangements between small biotech firms or academic laboratories (David) with multinational pharmaceutical corporations (Goliath) to discover, develop and commercialize innovative new drugs.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Robert Thong consults, speaks, and writes on business strategy, collaborations, and change in the bioscience sector. Over the past twenty-five years, he has worked with more than one hundred different pharmaceutical, biotech, medical device and healthcare organizations. During the 1990s, Robert worked in leading global management consultancies, serving multinational pharmaceutical and healthcare businesses in Europe and North America; he co-headed the Gemini Consulting (now Cap Gemini) Life Sciences Group and then led the European Bioscience Business Unit at COBA-Renaissance. In the 2000s, he led Datamonitor's Healthcare Division and founded two boutique management consultancies (NovaSecta, specializing in mid-sized pharmaceutical companies; and Unleash Team, focused on change management in scientific and technical organizations). He was a non-executive director on the board of Alpharma (an NYSE-listed mid-sized pharmaceutical corporation) from 2003 to 2006. Robert holds a Bachelor's degree in Mathematics from Imperial College London, and a Master's degree in Management from the Massachusetts Institute of Technology's Sloan School of Management. He publishes a regular blog and can be reached via the contact page on his website http: //scitechstrategy.com